Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 4010

1.

Concurrent, successful management of bipolar I disorder with comorbid alcohol dependence via aripiprazole long-acting injection: A case report.

Kurata T, Hashimoto T, Suzuki H.

Neuropsychopharmacol Rep. 2019 Jul 20. doi: 10.1002/npr2.12072. [Epub ahead of print]

PMID:
31325244
2.

Effect fingerprints of antipsychotic drugs on neural networks in vitro.

Görtz P, Henning U, Theiss S, Lange-Asschenfeldt C.

J Neural Transm (Vienna). 2019 Jul 18. doi: 10.1007/s00702-019-02050-8. [Epub ahead of print]

PMID:
31321550
3.

Digital aripiprazole or digital evergreening? A systematic review of the evidence and its dissemination in the scientific literature and in the media.

Cosgrove L, Cristea IA, Shaughnessy AF, Mintzes B, Naudet F.

BMJ Evid Based Med. 2019 Jul 18. pii: bmjebm-2019-111204. doi: 10.1136/bmjebm-2019-111204. [Epub ahead of print]

PMID:
31320322
4.

Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil NanoCrystal® Dispersion used for initiation of the long-acting antipsychotic aripiprazole lauroxil.

Hard ML, Wehr A, von Moltke L, Du Y, Farwick S, Walling DP, Sonnenberg J.

Ther Adv Psychopharmacol. 2019 Jul 2;9:2045125319859964. doi: 10.1177/2045125319859964. eCollection 2019.

5.

Conventional mood stabilizers and/or second-generation antipsychotic drugs in bipolar disorders: A population-based comparison of risk of treatment failure.

Tournier M, Neumann A, Pambrun E, Weill A, Chaffiol JP, Alla F, Bégaud B, Maura G, Verdoux H.

J Affect Disord. 2019 Jul 6;257:412-420. doi: 10.1016/j.jad.2019.07.054. [Epub ahead of print]

PMID:
31306992
6.

Dopamine receptor D2 activation suppresses the radiosensitizing effect of aripiprazole via activation of AMPK.

Lee H, Kang S, Sonn JK, Lim YB.

FEBS Open Bio. 2019 Jul 13. doi: 10.1002/2211-5463.12699. [Epub ahead of print]

7.

The effect of aripiprazole once-monthly on personal and social functioning: post hoc analyses of acute and long-term studies.

Peters-Strickland T, Baker RA, Such P, Zhang P, Madera JJ.

Neuropsychiatr Dis Treat. 2019 Jun 24;15:1659-1669. doi: 10.2147/NDT.S198241. eCollection 2019.

8.

Effect of long-acting aripiprazole monohydrate on inpatient encounters: A retrospective mirror image study.

Aguilar M, Malcolm B.

Ment Health Clin. 2019 Jul 1;9(4):258-262. doi: 10.9740/mhc.2019.07.258. eCollection 2019 Jul.

9.

Aripiprazole Combined with Lamotrigine in the Treatment of a Treatment-Resistant Schizophrenic Patient with Tardive Dyskinesia and Supersensitivity Psychosis.

Peretti CS, Chouinard G.

Psychother Psychosom. 2019 Jul 10:1-2. doi: 10.1159/000501130. [Epub ahead of print] No abstract available.

PMID:
31291629
10.

Off-Label Use of Second-generation Antipsychotics in Bipolar Disorder: A Survey of Italian Psychiatrists.

Salvi V, Cerveri G, Aguglia A, Calò S, Corbo M, Martinotti G, Serafini G, Signorelli MS, Aguglia E, Amore M, Biggio G, DI Sciascio G, Mencacci C.

J Psychiatr Pract. 2019 Jul;25(4):318-327. doi: 10.1097/PRA.0000000000000405.

PMID:
31291215
11.

Aripiprazole Toxicity With a Biphasic Course of Somnolence.

Gupta D, OʼHara C.

Pediatr Emerg Care. 2019 Jul 8. doi: 10.1097/PEC.0000000000001889. [Epub ahead of print]

PMID:
31290799
12.

Chronic unpredictable mild stress-induced behavioral changes are coupled with dopaminergic hyperfunction and serotonergic hypofunction in mouse models of depression.

Lu Q, Mouri A, Yang Y, Kunisawa K, Teshigawara T, Hirakawa M, Mori Y, Yamamoto Y, Libo Z, Nabeshima T, Saito K.

Behav Brain Res. 2019 Jul 6;372:112053. doi: 10.1016/j.bbr.2019.112053. [Epub ahead of print]

PMID:
31288060
13.

[Hypersexuality Induced by Aripiprazole].

Kozian R.

Psychiatr Prax. 2019 Jul 8. doi: 10.1055/a-0941-3874. [Epub ahead of print] German.

PMID:
31284315
14.

Innovative BRET assay reveals differential agonist-induced D2 receptor intracellular trafficking and arrestin-3 recruitment.

De Vries L, Finana F, Cathala C, Ronsin B, Cussac D.

Mol Pharmacol. 2019 Jul 2. pii: mol.119.115998. doi: 10.1124/mol.119.115998. [Epub ahead of print]

15.

Catatonic Schizophrenia: Cases with Possible Genetic Predisposition.

Tariq M, Afridi MI, Saleem D, Pirzada S.

Cureus. 2019 Apr 23;11(4):e4525. doi: 10.7759/cureus.4525.

16.

Potential Utility of Biased GPCR Signaling for Treatment of Psychiatric Disorders.

Komatsu H, Fukuchi M, Habata Y.

Int J Mol Sci. 2019 Jun 29;20(13). pii: E3207. doi: 10.3390/ijms20133207. Review.

17.

Hydrogen bond dynamics and conformational flexibility in antipsychotics.

Pereira JEM, Eckert J, Rudic S, Yu D, Mole R, Tsapatsaris N, Bordallo HN.

Phys Chem Chem Phys. 2019 Jul 17;21(28):15463-15470. doi: 10.1039/c9cp02456e.

PMID:
31257373
18.

Factors That Affect Continuation of Antipsychotic Long-Acting Injections.

Taniguchi M, Hatano M, Kamei H, Inagaki R, Yamada S.

Biol Pharm Bull. 2019;42(7):1098-1101. doi: 10.1248/bpb.b19-00001.

19.

Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone.

Corponi F, Fabbri C, Bitter I, Montgomery S, Vieta E, Kasper S, Pallanti S, Serretti A.

Eur Neuropsychopharmacol. 2019 Jun 26. pii: S0924-977X(19)30266-4. doi: 10.1016/j.euroneuro.2019.06.008. [Epub ahead of print] Review.

PMID:
31255396
20.

Supplemental Content

Loading ...
Support Center